FDA database reveals many rheumatic and musculoskeletal adverse events on immunotherapiesJune 15, 2018Mixed TopicsPatient & Survivor CareImmunotherapy
FDA approves pembrolizumab for relapsed/refractory PMBCLJune 14, 2018Lymphoma & Plasma Cell Disorders
Protein activation could predict renal cell carcinoma recurrenceJune 14, 2018Renal Cell CarcinomaGenitourinary Cancer
PREOPANC-1: Early findings suggest benefit with preop chemo in pancreatic cancerJune 13, 2018GastroenterologyGastrointestinal Cancer
